Was Vistagen Therapeutics Inc (VTGN)’s session last reading good?

Arcelia Reed

While Vistagen Therapeutics Inc has overperformed by 6.04%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VTGN rose by 8.78%, with highs and lows ranging from $5.14 to $0.63, whereas the simple moving average fell by -75.44% in the last 200 days.

On December 17, 2025, William Blair Downgraded Vistagen Therapeutics Inc (NASDAQ: VTGN) to Mkt Perform. A report published by Stifel on December 17, 2025, Downgraded its rating to ‘Hold’ for VTGN. Jefferies December 07, 2023d its ‘Hold’ rating to ‘Buy’ for VTGN, as published in its report on December 07, 2023. Maxim Group’s report from August 07, 2023 suggests a price prediction of $30 for VTGN shares, giving the stock a ‘Buy’ rating. William Blair also rated the stock as ‘Mkt Perform’.

Analysis of Vistagen Therapeutics Inc (VTGN)

Further, the quarter-over-quarter increase in sales is 207.14%, showing a positive trend in the upcoming months.

Vistagen Therapeutics Inc’s future performance can be predicted by a variety of well-rounded types of analysis and research, with equity being one of the most crucial ones. The goal here is to ensure that your current return on equity of -46.28% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 5.79, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.

For any stock, average volume can be an extremely valuable indicator of volatility, and VTGN is registering an average volume of 2.44M. On a monthly basis, the volatility of the stock is set at 11.00%, whereas on a weekly basis, it is put at 9.75%, with a loss of -1.15% over the past seven days. Furthermore, long-term investors anticipate a median target price of $0.97, showing growth from the present price of $0.72, which can serve as yet another indication of whether VTGN is worth investing in or should be passed over.

How Do You Analyze Vistagen Therapeutics Inc Shares?

Besides checking the fundamentals, you should also know how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 14.78%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 44.98% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.

US Post News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.